Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Pepper

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|November 28, 2008
Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemiaChristopher Jenkins, Saman Hewamana, Amanda Gilkes, et al.
RSC Medicinal Chemistry|May 30, 2025
Design, synthesis and evaluation of pyrrolobenzodiazepine (PBD)-based PROTAC conjugates for the selective degradation of the NF-κB RelA/p65 subunitPeiqin Jin, Md Mahbub Hasan, Andrea G S Pepper, et al.
Leukemia|February 1, 2019
Telomere length predicts for outcome to FCR chemotherapy in CLLKevin Norris, Peter Hillmen, Andrew Rawstron, et al.
European Journal of Haematology|November 15, 2002
Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiationChris Pepper, Khalida Ali, Alun Thomas, et al.
British Journal of Haematology|November 9, 2019
Increased frequency of CD4<sup>+</sup> PD-1<sup>+</sup> HLA-DR<sup>+</sup> T cells is associated with disease progression in CLLLauren Elston, Chris Fegan, Robert Hills, et al.
Cancer Research|June 24, 2011
A novel tumor antigen derived from enhanced degradation of bax protein in human cancersCláudia Trindade Nunes, Kelly L Miners, Garry Dolton, et al.
Molecular Cancer Therapeutics|June 3, 2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomibElisabeth J Walsby, Guy Pratt, Saman Hewamana, et al.
Blood Cancer Journal|July 4, 2024
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing dataRichard Norris, John Jones, Erika Mancini, et al.
British Journal of Haematology|September 27, 2003
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemiaJane Starczynski, Chris Pepper, Guy Pratt, et al.
Pacing and Clinical Electrophysiology : PACE|April 12, 2006
X-ray dose reduction in fluoroscopically guided electrophysiology proceduresAndrew G Davies, Arnold R Cowen, Stephen M Kengyelics, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|November 28, 2008
Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemiaChristopher Jenkins, Saman Hewamana, Amanda Gilkes, et al.
RSC Medicinal Chemistry|May 30, 2025
Design, synthesis and evaluation of pyrrolobenzodiazepine (PBD)-based PROTAC conjugates for the selective degradation of the NF-κB RelA/p65 subunitPeiqin Jin, Md Mahbub Hasan, Andrea G S Pepper, et al.
Leukemia|February 1, 2019
Telomere length predicts for outcome to FCR chemotherapy in CLLKevin Norris, Peter Hillmen, Andrew Rawstron, et al.
European Journal of Haematology|November 15, 2002
Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiationChris Pepper, Khalida Ali, Alun Thomas, et al.
British Journal of Haematology|November 9, 2019
Increased frequency of CD4<sup>+</sup> PD-1<sup>+</sup> HLA-DR<sup>+</sup> T cells is associated with disease progression in CLLLauren Elston, Chris Fegan, Robert Hills, et al.
Cancer Research|June 24, 2011
A novel tumor antigen derived from enhanced degradation of bax protein in human cancersCláudia Trindade Nunes, Kelly L Miners, Garry Dolton, et al.
Molecular Cancer Therapeutics|June 3, 2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomibElisabeth J Walsby, Guy Pratt, Saman Hewamana, et al.
Blood Cancer Journal|July 4, 2024
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing dataRichard Norris, John Jones, Erika Mancini, et al.
British Journal of Haematology|September 27, 2003
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemiaJane Starczynski, Chris Pepper, Guy Pratt, et al.
Pacing and Clinical Electrophysiology : PACE|April 12, 2006
X-ray dose reduction in fluoroscopically guided electrophysiology proceduresAndrew G Davies, Arnold R Cowen, Stephen M Kengyelics, et al.
Pageof 12